AHA omega-3 statement
This article was originally published in The Tan Sheet
Executive Summary
"Evidence from prospective secondary prevention trials suggests" eicosapentaenoic acid plus docosahexaenoic acid "significantly reduce subsequent cardiac and all-cause mortality," AHA scientific statement in Nov. 19 Circulation says. Penny Kris-Etherton, PhD, et al., suggest while a dietary approach to increase omega-3 fatty acid intake "is preferable," supplements may be considered for those who cannot consume the recommended .5 g/d to 1.8 g/d through fish alone. However, researchers note "additional studies are needed to confirm and further define the health benefits of omega-3 fatty acid supplements for both primary and secondary prevention" of coronary disease. Patients taking more than 3 g of EPA + DHA from supplements "should do so only under a physician's care," Kris-Etherton et al. add...
You may also be interested in...
OMB omega-3 request
OMB urges HHS, USDA to modify the Dietary Guidelines and Food Guide Pyramid to include new information stating omega-3 fatty acids may reduce the risk of coronary heart disease, while trans fatty acids may increase risk of CHD, according to May 28 1"prompt" letter. OMB bases its request on "epidemiologic and clinical studies finding that an increase in consumption of omega-3 fatty acids results in reduced deaths due to CHD." OMB also points to American Heart Association's recent revision of its dietary guidelines to recommend eating fish, which is high in omega-3 fatty acids, twice weekly (2"The Tan Sheet" Dec. 2, 2002, In Brief). "Prompt" letter, which is used by Bush Administration to highlight issues considered worthy of priority status, requests meeting "in the next few weeks to discuss this issue"...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.